Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

NEURACEQ Drug Profile

« Back to Dashboard

Which patents cover Neuraceq, and what substitute generic drugs are available?

Neuraceq is a drug marketed by Piramal Imaging and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-eight patent family members in twenty-three countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

Summary for Tradename: NEURACEQ

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list1
Patent Applications: see list8
Drug Prices:see details
DailyMed Link:NEURACEQ at DailyMed

Pharmacology for Tradename: NEURACEQ

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes7,807,135► SubscribeYY ► Subscribe
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NEURACEQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
8,465,726Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEURACEQ

Country Document Number Estimated Expiration
South Africa200705104► Subscribe
Denmark2213652► Subscribe
Luxembourg92647► Subscribe
Slovenia2213652► Subscribe
World Intellectual Property Organization (WIPO)2006078384► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEURACEQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0719Netherlands► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140224
C0012France► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
2015 00018Denmark► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140224
647Luxembourg► SubscribePRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
90005-3Sweden► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc